In the latest trading session, 24.04 million GT Biopharma Inc (NASDAQ:GTBP) shares changed hands as the company’s beta touched 0.62. With the company’s most recent per share price at $2.49 changing hands around $0.46 or 22.56% at last look, the market valuation stands at $5.56M. GTBP’s current price is a discount, trading about -328.11% off its 52-week high of $10.66. The share price had its 52-week low at $1.72, which suggests the last value was 30.92% up since then.

Analysts gave the GT Biopharma Inc (GTBP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended GTBP as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. GT Biopharma Inc’s EPS for the current quarter is expected to be 0.

GT Biopharma Inc (NASDAQ:GTBP) trade information

Instantly GTBP is in green as seen in intraday trades today. With action 18.48%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -18.43%, with the 5-day performance at 18.48% in the green. However, in the 30-day time frame, GT Biopharma Inc (NASDAQ:GTBP) is 2.81% up.

GT Biopharma Inc (NASDAQ:GTBP)’s Major holders

Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund. With 11.04 shares estimated at $27266.0 under it, the former controlled 0.49% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.47% of the shares, roughly 10.5 shares worth around $25944.0.